drugset / Trial / NCT02442570
A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate safety and clinical efficacy of DC-TAB in multiple sclerosis.
Timeline
- Start
- 2012-09
- Primary completion
- 2014-06
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | alpha B-crystallin | Protein / enzyme biologic | 7.5 mg | Intravenous |
| Comparator | alpha B-crystallin | Protein / enzyme biologic | 12.5 mg | Intravenous |
| Comparator | alpha B-crystallin | Protein / enzyme biologic | 17.5 mg | Intravenous |